Collaborate with usWhat’s new?
Insights

Defining the future of Clinical Care.

Our industry-leading approach is paving the way for personalized, patient-centric treatments.

Publication

Evolution of Digital Therapeutics (DTx) Utilizing Clinical Trials, Reverse Translation, and In Silico Methods for Enhanced Product Lifecycle Management in Chronic Disorders With Episodic Manifestations (CDEM)

Presented at the International Society for CNS Clinical Trials and Methodology (ISCTM) Annual Meeting, February 2023.

Authors:

Dahlem et al.

Related subjects:

CT-132MigrainePosters & Presentations

Contact:

To request information regarding this poster, please contact medicalaffairs@clicktherapeutics.com

Recent publications

View all

01.27.2025

Schizophrenia
CT-155
Prescription Digital Therapeutics
Peer-reviewed Manuscripts

Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies

By Snipes et al.

01.10.2025

Prescription Digital Therapeutics

Editorial: Prescription digital therapeutics in psychiatry

By Colbert et al.

08.20.2024

CT-152
Rejoyn
Depression
Prescription Digital Therapeutics
Peer-reviewed Manuscripts

Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study

By Rothman et al.

04.13.2024

Prescription Digital Therapeutics
Migraine
Posters & Presentations

Migraine-specific Health Care Resource Utilization (HCRU) in the US: A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases

By Petrova et al.

04.13.2024

Migraine
CT-132
Posters & Presentations

Comparison of Health Care Resource Utilization (HCRU) of Chronic Migraine and Other Migraine Patients: A Retrospective Claims Analysis.

By Kuka et al.

04.13.2024

Migraine
CT-132
Posters & Presentations

US Economic Burden of Migraine: A Retrospective Claims Analysis

By Besedina et al.

04.09.2024

CT-132
Migraine
Posters & Presentations

A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases to Elucidate Migraine-specific Health Care Resource Utilization (HCRU), and Migraine-specific Costs of Care (P1-12.005)

By Gupta et al.

02.21.2024

CT-132
Migraine
Posters & Presentations

Efficacy of Recruitment Techniques for a Decentralized Trial of a Digital Therapeutic for Migraine

By Colbert et al.

09.06.2023

Schizophrenia
Prescription Digital Therapeutics
Posters & Presentations

A Pilot Study to Assess if Patients With Schizophrenia can Form a Working Alliance With a Digital Therapeutic

By Campellone et al.

06.15.2023

Migraine
Posters & Presentations
CT-132

Current Migraine Headache Treatment Characteristics in a Nationally Representative Sample of U.S. Adults

By Gupta et al.

01.27.2025

Schizophrenia
CT-155
Prescription Digital Therapeutics
Peer-reviewed Manuscripts

Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies

By Snipes et al.

01.10.2025

Prescription Digital Therapeutics

Editorial: Prescription digital therapeutics in psychiatry

By Colbert et al.

08.20.2024

CT-152
Rejoyn
Depression
Prescription Digital Therapeutics
Peer-reviewed Manuscripts

Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study

By Rothman et al.

04.13.2024

Prescription Digital Therapeutics
Migraine
Posters & Presentations

Migraine-specific Health Care Resource Utilization (HCRU) in the US: A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases

By Petrova et al.

04.13.2024

Migraine
CT-132
Posters & Presentations

Comparison of Health Care Resource Utilization (HCRU) of Chronic Migraine and Other Migraine Patients: A Retrospective Claims Analysis.

By Kuka et al.

04.13.2024

Migraine
CT-132
Posters & Presentations

US Economic Burden of Migraine: A Retrospective Claims Analysis

By Besedina et al.

04.09.2024

CT-132
Migraine
Posters & Presentations

A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases to Elucidate Migraine-specific Health Care Resource Utilization (HCRU), and Migraine-specific Costs of Care (P1-12.005)

By Gupta et al.

02.21.2024

CT-132
Migraine
Posters & Presentations

Efficacy of Recruitment Techniques for a Decentralized Trial of a Digital Therapeutic for Migraine

By Colbert et al.

09.06.2023

Schizophrenia
Prescription Digital Therapeutics
Posters & Presentations

A Pilot Study to Assess if Patients With Schizophrenia can Form a Working Alliance With a Digital Therapeutic

By Campellone et al.

06.15.2023

Migraine
Posters & Presentations
CT-132

Current Migraine Headache Treatment Characteristics in a Nationally Representative Sample of U.S. Adults

By Gupta et al.

View all

Discover our products

CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch
AspyreRx

AspyreRx

AspyreRx™

Indication

Type 2 Diabetes

Collaborator

Phase

FDA Cleared
CT-132

CT-132

Indication

Episodic Migraine

Collaborator

Phase

Regulatory Review
CT-155

CT-155

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 3: Pivotal
CT-156

CT-156

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery
CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch
AspyreRx

AspyreRx

AspyreRx™

Indication

Type 2 Diabetes

Collaborator

Phase

FDA Cleared
CT-132

CT-132

Indication

Episodic Migraine

Collaborator

Phase

Regulatory Review
CT-155

CT-155

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 3: Pivotal
CT-156

CT-156

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery

Stay up to date with news and updates